| | |
PER ADS
|
| |
TOTAL
|
| ||||||
Public offering price
|
| | | $ | 7.00 | | | | | $ | 23,999,997 | | |
承保折扣和佣金(1)
|
| | | $ | 0.42 | | | | | $ | 1,440,000 | | |
未扣除费用的收益
|
| | | $ | 6.58 | | | | | $ | 22,559,997 | | |
| | |
Page
|
| |||
PROSPECTUS SUMMARY
|
| | | | 1 | | |
THE OFFERING
|
| | | | 13 | | |
SUMMARY FINANCIAL DATA
|
| | | | 16 | | |
RISK FACTORS
|
| | | | 18 | | |
有关前瞻性陈述的警示说明
|
| | | | 100 | | |
市场、行业等数据
|
| | | | 102 | | |
USE OF PROCEEDS
|
| | | | 103 | | |
DIVIDEND POLICY
|
| | | | 104 | | |
CAPITALIZATION
|
| | | | 105 | | |
DILUTION
|
| | | | 106 | | |
选定的财务数据
|
| | | | 108 | | |
管理层对财务状况和经营成果的讨论和分析
|
| | | | 110 | | |
BUSINESS
|
| | | | 126 | | |
MANAGEMENT
|
| | | | 204 | | |
关联方交易
|
| | | | 218 | | |
主要股东
|
| | | | 219 | | |
股本说明
|
| | | | 221 | | |
美国存托股份说明
|
| | | | 234 | | |
未来有资格出售的普通股和美国存托凭证
|
| | | | 242 | | |
TAXATION
|
| | | | 245 | | |
UNDERWRITING
|
| | | | 255 | | |
EXPENSES OF THE OFFERING
|
| | | | 262 | | |
LEGAL MATTERS
|
| | | | 263 | | |
EXPERTS
|
| | | | 264 | | |
诉讼程序的送达和民事责任的执行
|
| | | | 265 | | |
您可以在哪里找到更多信息
|
| | | | 266 | | |
财务报表索引
|
| | | | F-1 | | |
| | |
For the Years Ended
December 31, |
| |
Three Months Ended
June 30, |
| |
Six Months Ended
June 30, |
| |||||||||||||||||||||||||||||||||
|
(单位为千美元,每股数据除外)
|
| |||||||||||||||||||||||||||||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |
2020
|
| |
2021
|
| |
2020
|
| |
2021
|
| |||||||||||||||||||||||
研发费用
|
| | | $ | 3,729 | | | | | $ | 8,216 | | | | | $ | 10,902 | | | | | $ | 2,570 | | | | | $ | 5,111 | | | | | $ | 5,080 | | | | | $ | 9,004 | | |
一般和行政费用
|
| | | | 1,898 | | | | | | 2,647 | | | | | | 5,666 | | | | | | 1,372 | | | | | | 1,915 | | | | | | 2,153 | | | | | | 3,197 | | |
Operating loss
|
| | | | (5,627) | | | | | | (10,863) | | | | | | (16,568) | | | | | | (3,942) | | | | | | (7,026) | | | | | | (7,233) | | | | | | (12,201) | | |
Finance income
|
| | | | 76 | | | | | | 65 | | | | | | 216 | | | | | | 6 | | | | | | 33 | | | | | | 22 | | | | | | 1,005 | | |
Finance expense
|
| | | | (719) | | | | | | (1,222) | | | | | | 223 | | | | | | — | | | | | | (495) | | | | | | (4) | | | | | | (792) | | |
Net loss before tax
|
| | | | (6,270) | | | | | | (12,020) | | | | | | (16,575) | | | | | | (3,936) | | | | | | (7,488) | | | | | | (7,215) | | | | | | (11,988) | | |
Income taxes
|
| | | | 735 | | | | | | 825 | | | | | | 1,557 | | | | | | 296 | | | | | | 669 | | | | | | 476 | | | | | | 1,076 | | |
Net loss for the period
|
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (15,018) | | | | | $ | (3,640) | | | | | $ | (6,819) | | | | | $ | (6,739) | | | | | $ | (10,912) | | |
Net loss attributable to
equity holders of Evaxion Biotech A/S |
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (15,018) | | | | | $ | (3,640) | | | | | $ | (6,819) | | | | | $ | (6,739) | | | | | $ | (10,912) | | |
Loss per share – basic and diluted(1)
|
| | | $ | (0.43) | | | | | $ | (0.81) | | | | | $ | (0.97) | | | | | $ | (0.24) | | | | | $ | (0.36) | | | | | $ | (0.44) | | | | | $ | (0.59) | | |
(in thousands)
|
| |
June 30, 2021
|
| |||||||||
|
Actual
|
| |
As Adjusted(1)
|
| ||||||||
合并财务状况表: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 18,799 | | | | | $ | 40,555 | | |
Total assets
|
| | | | 27,657 | | | | | | 49,149 | | |
Total liabilities
|
| | | | 5,828 | | | | | | 5,828 | | |
Share capital
|
| | | | 3,132 | | | | | | 3,680 | | |
Other reserves
|
| | | | 56,168 | | | | | | 77,112 | | |
Accumulated deficit
|
| | | | (37,471) | | | | | | (37,471) | | |
Total equity
|
| | | $ | 21,829 | | | | | $ | 43,321 | | |
(除每股和每股数据外,以千为单位)
|
| |
As of June 30, 2021
|
| |||||||||
|
Actual
|
| |
As Adjusted
|
| ||||||||
现金和现金等价物
|
| | | $ | 18,799 | | | | | $ | 40,555 | | |
Total liabilities
|
| | | | 5,828 | | | | | | 5,828 | | |
Equity
|
| | | | | | | | | | | | |
Share capital
|
| | | | 3,132 | | | | | | 3,680 | | |
Other reserves
|
| | | | 56,168 | | | | | | 77,112 | | |
Accumulated deficit
|
| | | | (37,471) | | | | | | (37,471) | | |
Total equity
|
| | | | 21,829 | | | | | | 43,321 | | |
Total capitalization(1)
|
| | | $ | 27,657 | | | | | $ | 49,149 | | |
|
每个美国存托股份的公开发行价
|
| | | | | | | | | $ | 7.00 | | |
|
截至2021年6月30日美国存托股份的历史有形账面净值
|
| | | | 1.12 | | | | | | | | |
|
每美国存托股份有形账面净值增加可归因于新投资者参与
in the offering |
| | | | 0.79 | | | | | | | | |
|
美国存托股份上市后的调整后有形账面净值
|
| | | | | | | | | | 1.91 | | |
|
按美国存托股份向参与此次发行的新投资者摊薄
|
| | | | | | | | | $ | 5.09 | | |
| | |
Ordinary Shares
Purchased |
| |
Total Consideration
|
| |
Average
Price Per Share |
| |
Average
Price Per ADS |
| ||||||||||||||||||||||||
|
Number
|
| |
Percent
|
| |
Amount
|
| |
Percent
|
| ||||||||||||||||||||||||||
现有股东
|
| | | | 19,198,668 | | | | | | 84.8% | | | | | $ | 59,300,000 | | | | | | 71.2% | | | | | $ | 3.09 | | | | | $ | 3.09 | | |
New investors
|
| | | | 3,428,571 | | | | | | 15.2% | | | | | | 23,999,997 | | | | | | 28.8% | | | | | $ | 7.00 | | | | | $ | 7.00 | | |
Total
|
| | | | 22,627,239 | | | | | | 100% | | | | | $ | 83,299,997 | | | | | | 100% | | | | | $ | 3.68 | | | | | $ | 3.68 | | |
| | |
For the Years Ended
December 31, |
| |
Three Months Ended
June 30, |
| |
Six Months Ended
June 30, |
| |||||||||||||||||||||||||||||||||
|
(单位为千美元,每股数据除外)
|
| |||||||||||||||||||||||||||||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |
2020
|
| |
2021
|
| |
2020
|
| |
2021
|
| |||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | |
(unaudited)
|
| |
(unaudited)
|
| ||||||||||||||||||||
研发费用
|
| | | $ | 3,729 | | | | | $ | 8,216 | | | | | $ | 10,902 | | | | | $ | 2,570 | | | | | $ | 5,111 | | | | | $ | 5,080 | | | | | $ | 9,004 | | |
一般和行政费用
|
| | | | 1,898 | | | | | | 2,647 | | | | | | 5,666 | | | | | | 1,372 | | | | | | 1,915 | | | | | | 2,153 | | | | | | 3,197 | | |
Operating loss
|
| | | | (5,627) | | | | | | (10,863) | | | | | | (16,568) | | | | | | (3,942) | | | | | | (7,026) | | | | | | (7,233) | | | | | | (12,201) | | |
Finance income
|
| | | | 76 | | | | | | 65 | | | | | | 216 | | | | | | 6 | | | | | | 33 | | | | | | 22 | | | | | | 1,005 | | |
Finance expense
|
| | | | (719) | | | | | | (1,222) | | | | | | (223) | | | | | | — | | | | | | (495) | | | | | | (4) | | | | | | (792) | | |
Net loss before tax
|
| | | | (6,270) | | | | | | (12,020) | | | | | | (16,575) | | | | | | (3,936) | | | | | | (7,488) | | | | | | (7,215) | | | | | | (11,988) | | |
Income taxes
|
| | | | 735 | | | | | | 825 | | | | | | 1,557 | | | | | | 296 | | | | | | 669 | | | | | | 476 | | | | | | 1,076 | | |
Net loss for the period
|
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (15,018) | | | | | $ | (3,640) | | | | | $ | (6,819) | | | | | $ | (6,739) | | | | | $ | (10,912) | | |
Net loss attributable to
equity holders of Evaxion Biotech A/S |
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (15,018) | | | | | $ | (3,640) | | | | | $ | (6,819) | | | | | $ | (6,739) | | | | | $ | (10,912) | | |
Loss per share – basic and diluted
|
| | | $ | (0.43) | | | | | $ | (0.81) | | | | | $ | (0.97) | | | | | $ | (0.24) | | | | | $ | (0.36) | | | | | $ | (0.44) | | | | | $ | (0.59) | | |
(in thousands)
|
| |
As of
|
| |||||||||||||||||||||
|
December 31,
|
| |
June 30,
|
| ||||||||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |
2021
|
| ||||||||||||||
| | | | | | | | | | | | | | | | | | |
(unaudited)
|
| |||||
合并财务状况表: | | | | | | | | | | | | | | | | | | | | | | | | | |
现金和现金等价物
|
| | | $ | 7,433 | | | | | $ | 9,559 | | | | | $ | 5,834 | | | | | | 18,799 | | |
Total assets
|
| | | | 8,513 | | | | | | 11,084 | | | | | | 11,965 | | | | | $ | 27,657 | | |
Total liabilities
|
| | | | 9,444 | | | | | | 1,722 | | | | | | 4,927 | | | | | | 5,828 | | |
Share capital
|
| | | | 2,113 | | | | | | 2,481 | | | | | | 2,648 | | | | | $ | 3,132 | | |
Other reserves
|
| | | | 3,935 | | | | | | 22,693 | | | | | | 31,669 | | | | | | 56,168 | | |
Accumulated deficit
|
| | | | (6,979) | | | | | | (15,812) | | | | | | (27,279) | | | | | | (37,471) | | |
Total equity
|
| | | | (931) | | | | | | 9,362 | | | | | | 7,038 | | | | | | 21,829 | | |
| | |
Three Months Ended June 30,
|
| |||||||||||||||
| | |
2020
|
| |
2021
|
| |
Change
|
| |||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | | |
研发
|
| | | $ | 2,570 | | | | | $ | 5,111 | | | | | $ | 2,541 | | |
一般和行政
|
| | | | 1,372 | | | | | | 1,915 | | | | | | 543 | | |
总运营费用
|
| | | | 3,942 | | | | | | 7,026 | | | | | | 3,084 | | |
Operating loss
|
| | | | (3,942) | | | | | | (7,026) | | | | | | (3,084) | | |
Finance income
|
| | | | 6 | | | | | | 33 | | | | | | 27 | | |
Finance expenses
|
| | | | — | | | | | | (495) | | | | | | (495) | | |
Net loss before tax
|
| | | | (3,936) | | | | | | (7,488) | | | | | | (3,552) | | |
Income tax benefit
|
| | | | 296 | | | | | | 669 | | | | | | 373 | | |
Net loss for the period
|
| | | $ | (3,640) | | | | | $ | (6,819) | | | | | $ | (3,179) | | |
| | |
Six Months Ended June 30,
|
| |||||||||||||||
|
2020
|
| |
2021
|
| |
Change
|
| |||||||||||
|
(USD in thousands)
|
| |||||||||||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | | |
研发
|
| | | $ | 5,080 | | | | | $ | 9,004 | | | | | $ | 3,924 | | |
一般和行政
|
| | | | 2,153 | | | | | | 3,197 | | | | | | 1,044 | | |
总运营费用
|
| | | | 7,233 | | | | | | 12,201 | | | | | | 4,968 | | |
Operating loss
|
| | | | (7,233) | | | | | | (12,201) | | | | | | (4,968) | | |
Finance income
|
| | | | 22 | | | | | | 1,005 | | | | | | 983 | | |
Finance expenses
|
| | | | (4) | | | | | | (792) | | | | | | (788) | | |
Net loss before tax
|
| | | | (7,215) | | | | | | (11,988) | | | | | | (4,773) | | |
Income tax benefit
|
| | | | 476 | | | | | | 1,076 | | | | | | 600 | | |
Net loss for the period
|
| | | $ | (6,739) | | | | | $ | (10,912) | | | | | $ | (4,173) | | |
| | |
Years Ended December 31,
|
| |
Change
2019 vs 2018 |
| |
Change
2020 vs 2019 |
| |||||||||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||||||||||||||
|
(USD in thousands)
|
| |||||||||||||||||||||||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
研发
|
| | | $ | 3,729 | | | | | $ | 8,216 | | | | | $ | 10,902 | | | | | $ | 4,487 | | | | | $ | 2,686 | | |
一般和行政
|
| | | | 1,898 | | | | | | 2,647 | | | | | | 5,666 | | | | | | 749 | | | | | | 3,019 | | |
总运营费用
|
| | | | 5,627 | | | | | | 10,863 | | | | | | 16,568 | | | | | | 5,236 | | | | | | 5,705 | | |
Operating loss
|
| | | | (5,627) | | | | | | (10,863) | | | | | | (16,568) | | | | | | (5,236) | | | | | | (5,705) | | |
Finance income
|
| | | | 76 | | | | | | 65 | | | | | | 216 | | | | | | (11) | | | | | | 151 | | |
Finance expenses
|
| | | | (719) | | | | | | (1,222) | | | | | | (223) | | | | | | (503) | | | | | | 999 | | |
Net loss before tax
|
| | | | (6,270) | | | | | | (12,020) | | | | | | (16,575) | | | | | | (5,750) | | | | | | (4,555) | | |
Income taxes
|
| | | | 735 | | | | | | 825 | | | | | | 1,557 | | | | | | 90 | | | | | | 732 | | |
Net loss for the period
|
| | | $ | (5,535) | | | | | $ | (11,195) | | | | | $ | (15,018) | | | | | $ | (5,660) | | | | | $ | (3,823) | | |
| | |
Six Months Ended June 30,
|
| |||||||||
|
2020
|
| |
2021
|
| ||||||||
|
(USD in thousands)
|
| |||||||||||
Cash Flow Data: | | | | | | | | | | | | | |
经营活动中使用的净现金
|
| | | $ | (5,253) | | | | | $ | (11,523) | | |
投资活动中使用的净现金
|
| | | | (126) | | | | | | (822) | | |
净现金(用于)/由融资活动提供
|
| | | | (36) | | | | | | 25,217 | | |
现金和现金等价物净增加/(减少)
|
| | | $ | (5,415) | | | | | $ | (12,872) | | |
| | |
Years Ended December 31,
|
| |||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||
|
(USD in thousands)
|
| |||||||||||||||||
Cash Flow Data: | | | | | | | | | | | | | | | | | | | |
经营活动中使用的现金
|
| | | $ | (1,991) | | | | | $ | (7,019) | | | | | $ | (12,438) | | |
投资活动提供/使用的现金
|
| | | | 6 | | | | | | (68) | | | | | | (393) | | |
融资活动提供的现金
|
| | | | 9,027 | | | | | | 9,508 | | | | | | 8,818 | | |
现金及现金等价物净增(减)
|
| | | $ | 7,042 | | | | | $ | 2,421 | | | | | $ | (4,013) | | |
(USD in thousands)
|
| |
June 30, 2021
|
| |||||||||||||||||||||||||||||||||
|
Carrying
amount |
| |
Contractual
cash flows |
| |
|
| |
1 – 5 years
|
| |
>5 years
|
| |
Total
|
| ||||||||||||||||||||
Lease liabilities
|
| | | $ | 1,110 | | | | | $ | 1,641 | | | | | $ | 141 | | | | | $ | 592 | | | | | $ | 908 | | | | | $ | 1,641 | | |
Trade payables
|
| | | | 1,552 | | | | | | 1,552 | | | | | | 1,552 | | | | | | — | | | | | | — | | | | | | 1,552 | | |
Other payables
|
| | | | 3,113 | | | | | | 3,113 | | | | | | 3,113 | | | | | | — | | | | | | — | | | | | | 3,113 | | |
Total
|
| | | $ | 5,775 | | | | | $ | 6,306 | | | | | $ | 4,806 | | | | | $ | 592 | | | | | $ | 908 | | | | | $ | 6,306 | | |
| | |
Per warrant
grant date fair value (DKK) |
| |
Per warrant
grant date fair value (USD) |
| ||||||
优秀项目 | | | | | | | | | | | | | |
Grant (December 2016)
|
| | | | 20.91 | | | | | | 3.13 | | |
Grant (April 2017)
|
| | | | 24.05 | | | | | | 3.60 | | |
Grant (September 2017)
|
| | | | 28.71 | | | | | | 4.30 | | |
Grant (December 2017)
|
| | | | 28.71 | | | | | | 4.30 | | |
Granted (during 2018)
|
| | | | 37.05 | | | | | | 5.55 | | |
Granted (January 2019)
|
| | | | 37.05 | | | | | | 5.55 | | |
| | |
Per warrant
grant date fair value (DKK) |
| |
Per warrant
grant date fair value (USD) |
| ||||||
Granted (February 2019)
|
| | | | 42.57 | | | | | | 6.38 | | |
Granted (September 2019)
|
| | | | 56.35 | | | | | | 8.44 | | |
Granted (October 2019)
|
| | | | 56.97 | | | | | | 8.53 | | |
Granted (December 2019)
|
| | | | 57.48 | | | | | | 8.60 | | |
Granted (December 2020)
|
| | | | 56.75 | | | | | | 9.35 | | |
|
|
| |
|
|
Bacterial species
|
| |
In vivo
PoC |
| |
体内模型(小鼠挑战模型)
|
| |
IP
filed |
|
金黄色葡萄球菌
|
| |
✓
|
| |
致死性腹膜炎和皮肤脓肿模型
|
| |
✓
|
|
铜绿假单胞菌
|
| |
✓
|
| | 致死性腹膜炎和致死性急性肺炎模型 | | |
✓
|
|
非分型流感嗜血杆菌
|
| |
✓
|
| | 肺定植模型 | | |
✓
|
|
卡他莫拉氏菌
|
| |
✓
|
| | 致死性腹膜炎和肺定植模型 | | |
✓
|
|
淋病奈瑟菌
|
| |
✓
|
| | 阴道定植模型 | | |
✓
|
|
鲍曼不动杆菌
|
| |
✓
|
| | 致死性急性肺炎模型 | | |
✓
|
|
肺炎克雷伯菌
|
| |
✓
|
| | 致死性腹膜炎和致死性急性肺炎模型 | | |
✓
|
|
#
|
| |
Protein ID
|
| |
No. of
Experiments |
| |
No. of
Test Mice |
| |
No. of
Control Mice |
| |
%
Survival of Test Mice |
| |
%
Survival of Control Mice |
| |
Difference in
% Survival (Test vs. Control) |
| ||||||||||||||||||
1 | | | EDEN-1 | | | | | 4 | | | | | | 59 | | | | | | 60 | | | | | | 76% | | | | | | 28% | | | | | | 48% | | |
2 | | | EDEN-2 | | | | | 2 | | | | | | 24 | | | | | | 24 | | | | | | 58% | | | | | | 13% | | | | | | 46% | | |
3 | | | EDEN-3 | | | | | 3 | | | | | | 43 | | | | | | 44 | | | | | | 77% | | | | | | 32% | | | | | | 45% | | |
4 | | | EDEN-4 | | | | | 2 | | | | | | 28 | | | | | | 28 | | | | | | 68% | | | | | | 25% | | | | | | 43% | | |
5 | | | EDEN-5 | | | | | 2 | | | | | | 28 | | | | | | 28 | | | | | | 68% | | | | | | 25% | | | | | | 43% | | |
6 | | | EDEN-6 | | | | | 2 | | | | | | 27 | | | | | | 28 | | | | | | 85% | | | | | | 43% | | | | | | 42% | | |
7 | | | EDEN-7 | | | | | 3 | | | | | | 36 | | | | | | 36 | | | | | | 61% | | | | | | 19% | | | | | | 42% | | |
8 | | | EDEN-8 | | | | | 5 | | | | | | 61 | | | | | | 64 | | | | | | 51% | | | | | | 9% | | | | | | 41% | | |
9 | | | EDEN-9 | | | | | 3 | | | | | | 43 | | | | | | 44 | | | | | | 63% | | | | | | 30% | | | | | | 33% | | |
10 | | | EDEN-10 | | | | | 3 | | | | | | 36 | | | | | | 36 | | | | | | 69% | | | | | | 36% | | | | | | 33% | | |
11 | | | EDEN-11 | | | | | 3 | | | | | | 32 | | | | | | 35 | | | | | | 53% | | | | | | 20% | | | | | | 33% | | |
12 | | | EDEN-12 | | | | | 3 | | | | | | 42 | | | | | | 42 | | | | | | 62% | | | | | | 31% | | | | | | 31% | | |
13 | | | EDEN-13 | | | | | 3 | | | | | | 36 | | | | | | 36 | | | | | | 47% | | | | | | 28% | | | | | | 19% | | |
Function
|
| |
Number
|
| |||
临床研究与开发
|
| | | | 9 | | |
科学研究与开发
|
| | | | 33 | | |
Supporting Functions
|
| | | | 10 | | |
商业和商业发展
|
| | | | 5 | | |
TOTAL
|
| | |
|
57
|
| |
Region
|
| |
Number
|
| |||
Capital Region, Denmark
|
| | | | 55 | | |
New York, United States
|
| | | | 2 | | |
TOTAL
|
| | |
|
57
|
| |
Name
|
| |
Position
|
| |
Age
|
| |
Independent
|
| |
Year of first
appointment |
| |
Expiration
of current term |
| ||||||||||||
Marianne Søgaard(1)
|
| | | | 女主席 | | | | 53 | | | No | | | | | 2020 | | | | | | 2022 | | | |||
Steven Projan(1)(2)(3)
|
| | Member | | | 69 | | | | | 独立的 | | | | | | 2018 | | | | | | 2022 | | | |||
Roberto Prego(1)(2)
|
| | Member | | | 50 | | | | | 独立的 | | | | | | 2018 | | | | | | 2022 | | | |||
Lars Holtug(2)(3)
|
| | Member | | | 62 | | | | | 独立的 | | | | | | 2021 | | | | | | 2022 | | |
Name
|
| |
Age
|
| |
Position(s)
|
|
执行管理层: | | | | | | | |
Lars Staal Wegner, M.D.
|
| | 47 | | | 首席执行官 | |
Niels Iversen Møller, M.D.
|
| | 42 | | | 临时首席财务官兼首席业务官 | |
Glenn S. Vraniak(1)
|
| | 59 | | | 前首席财务官 | |
Erik Deichmann Heegaard,博士,DMSc
|
| | 54 | | | 首席医疗官 | |
Birgitte Rønø, Ph.D.
|
| | 45 | | | 首席科学官 | |
Andreas Holm Mattsson
|
| | 46 | | | 首席创新官 | |
(in thousands of USD)
|
| |
Years Ended
December 31, |
| |||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||
Lars Staal Wegner(CEO) | | | | | | | | | | | | | | | | | | | |
Salary
|
| | | | 220 | | | | | | 238 | | | | | | 321 | | |
Bonus
|
| | | | 6 | | | | | | – | | | | | | – | | |
其他员工福利
|
| | | | – | | | | | | 650 | | | | | | 621 | | |
Total
|
| | | | 226 | | | | | | 888 | | | | | | 942 | | |
Glenn S. Vraniak (CFO)(1) | | | | | | | | | | | | | | | | | | | |
Salary
|
| | | | – | | | | | | 88 | | | | | | 350 | | |
Bonus
|
| | | | – | | | | | | – | | | | | | 43 | | |
Other employee benefits(2)
|
| | | | – | | | | | | 204 | | | | | | 1,045 | | |
Total
|
| | | | – | | | | | | 292 | | | | | | 1,438 | | |
Niels Iverson Møller (CBO)(3) | | | | | | | | | | | | | | | | | | | |
Salary
|
| | | | 173 | | | | | | 175 | | | | | | 202 | | |
Bonus
|
| | | | 5 | | | | | | – | | | | | | 11 | | |
其他员工福利
|
| | | | – | | | | | | – | | | | | | 0 | | |
Total
|
| | | | 178 | | | | | | 175 | | | | | | 213 | | |
安德烈亚斯·霍姆·马特森(CIO) | | | | | | | | | | | | | | | | | | | |
Salary
|
| | | | 179 | | | | | | 175 | | | | | | 202 | | |
(in thousands of USD)
|
| |
Years Ended
December 31, |
| |||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||
Bonus
|
| | | | 5 | | | | | | – | | | | | | 11 | | |
其他员工福利
|
| | | | – | | | | | | – | | | | | | 0 | | |
Total
|
| | | | 184 | | | | | | 175 | | | | | | 213 | | |
Erik Deichmann Heegaard,Ph.D.,DMSc(CMO)(3) | | | | | | | | | | | | | | | | | | | |
Salary
|
| | | | – | | | | | | – | | | | | | – | | |
Bonus
|
| | | | – | | | | | | – | | | | | | – | | |
其他员工福利
|
| | | | – | | | | | | – | | | | | | – | | |
Total
|
| | | | – | | | | | | – | | | | | | – | | |
Birgitte Rønø, Ph.D. | | | | | | | | | | | | | | | | | | | |
Salary
|
| | | | 113 | | | | | | 131 | | | | | | 159 | | |
Bonus
|
| | | | – | | | | | | – | | | | | | – | | |
其他员工福利
|
| | | | 14 | | | | | | 30 | | | | | | 68 | | |
Total
|
| | | | 127 | | | | | | 161 | | | | | | 227 | | |
|
(in thousands of USD)
|
| |
Years Ended
December 31, |
| |||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||
不包括执行管理层和董事会的员工成本
|
| | | | | | | | | | | | | | | | | | |
Salaries
|
| | | | 1,112 | | | | | | 1,919 | | | | | | 2,717 | | |
Cash bonus
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | 387 | | | | | | 1,055 | | | | | | 1,484 | | |
Pensions
|
| | | | 70 | | | | | | 96 | | | | | | 206 | | |
其他社保缴费
|
| | | | 10 | | | | | | 12 | | | | | | 17 | | |
Other staff costs
|
| | | | 133 | | | | | | 176 | | | | | | 196 | | |
员工总成本,不包括执行管理层和董事会
|
| | | | 1,712 | | | | | | 3,258 | | | | | | 4,620 | | |
高管薪酬 | | | | | | | | | | | | | | | | | | | |
Salaries
|
| | | | 621 | | | | | | 900 | | | | | | 1,234 | | |
Cash bonus
|
| | | | – | | | | | | – | | | | | | 65 | | |
基于股份的薪酬
|
| | | | 1,157 | | | | | | 956 | | | | | | 1,565 | | |
Pensions
|
| | | | – | | | | | | – | | | | | | – | | |
其他社保缴费
|
| | | | – | | | | | | – | | | | | | – | | |
Other staff costs
|
| | | | – | | | | | | – | | | | | | – | | |
高管薪酬总额
|
| | | | 1,778 | | | | | | 1,856 | | | | | | 2,864 | | |
董事会薪酬 | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
(in thousands of USD)
|
| |
Years Ended
December 31, |
| |||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | 525 | | | | | | 351 | | | | | | 359 | | |
董事会薪酬总额
|
| | | | 525 | | | | | | 351 | | | | | | 359 | | |
Total employee costs
|
| | | | 4,015 | | | | | | 5,465 | | | | | | 7,843 | | |
在全面损失表中确认如下: | | | | | | | | | | | | | | | | | | | |
研发费用
|
| | | | 2,652 | | | | | | 3,607 | | | | | | 4,833 | | |
一般和行政费用
|
| | | | 1,363 | | | | | | 1,858 | | | | | | 3,007 | | |
Total employee costs
|
| | | | 4,015 | | | | | | 5,465 | | | | | | 7,840 | | |
全职员工平均人数
|
| | | | 18 | | | | | | 25 | | | | | | 33 | | |
截至12月31日的全职员工人数
|
| | | | 20 | | | | | | 36 | | | | | | 35 | | |
(in thousands in USD)
|
| |
Years Ended
December 31, |
| |||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||
Marianne Søgaard(1) | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | – | | | | | | – | | | | | | 12 | | |
Total
|
| | | | – | | | | | | – | | | | | | 12 | | |
Kim Bjoernstrup(董事会主席)(2) | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | – | | | | | | – | | | | | | 52 | | |
Total
|
| | | | – | | | | | | – | | | | | | 52 | | |
Helen M. Boudreau(3) | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | – | | | | | | – | | | | | | 48 | | |
Total
|
| | | | – | | | | | | – | | | | | | 48 | | |
Roberto Prego | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | – | | | | | | 61 | | | | | | 62 | | |
Total
|
| | | | – | | | | | | 61 | | | | | | 62 | | |
Steven Projan | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | 138 | | | | | | 62 | | | | | | 98 | | |
Total
|
| | | | 138 | | | | | | 62 | | | | | | 98 | | |
Jo Ann Suzich(4) | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
(in thousands in USD)
|
| |
Years Ended
December 31, |
| |||||||||||||||
|
2018
|
| |
2019
|
| |
2020
|
| |||||||||||
基于股份的薪酬
|
| | | | – | | | | | | 63 | | | | | | 26 | | |
Total
|
| | | | – | | | | | | 63 | | | | | | 26 | | |
托马斯·威廉·威隆尼斯 | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | – | | | | | | 166 | | | | | | 60 | | |
Total
|
| | | | – | | | | | | 166 | | | | | | 60 | | |
Lars Holtug(4) | | | | | | | | | | | | | | | | | | | |
Board and committee fees
|
| | | | – | | | | | | – | | | | | | – | | |
Travel allowance
|
| | | | – | | | | | | – | | | | | | – | | |
基于股份的薪酬
|
| | | | – | | | | | | – | | | | | | – | | |
Total
|
| | | | – | | | | | | – | | | | | | – | | |
|
Name
|
| |
Grant Date
|
| |
Number of Ordinary
Shares Underlying Warrants(2) |
| |
Warrant
Exercise Price DKK |
| |
Warrant
Expiration Date |
| |||
Marianne Søgaard
(Chairwoman) |
| | 2018/2019/2020 | | | | | 94,320 | | | |
1
|
| |
December 31, 2036
|
|
Lars Holtug (director)
|
| | 2021 | | | | | 0 | | | |
1
|
| |
–
|
|
Roberto Prego (director)
|
| | 2017/2018/2020 | | | | | 27,036 | | | |
1
|
| |
December 31, 2036
|
|
Steven Projan (director)
|
| | 2018/2019/2020 | | | | | 42,048 | | | |
1
|
| |
December 31, 2036
|
|
Lars Staal Wegner (CEO)
|
| | 2016/2017/2018/2020 | | | | | 852,264 | | | |
1
|
| |
December 31, 2036
|
|
Niels Iverson Møller (CBO)
|
| | – | | | | | 0 | | | |
–
|
| |
–
|
|
Andreas Holm Mattson (CIO)
|
| | – | | | | | 0 | | | |
–
|
| |
–
|
|
Glenn S. Vraniak (CFO)(1)
|
| | 2019 | | | | | 150,660 | | | |
1
|
| |
December 31, 2036
|
|
Erik Deichmann Heegaard(CMO)
|
| | 2021 | | | | | 62,147 | | | |
1
|
| |
December 31, 2031
|
|
Birgitte Rønø (CSO)
|
| | 2017/2018/2019/2020 | | | | | 29,376 | | | |
1
|
| |
December 31, 2036
|
|
Board Member
|
| |
Position
|
| |
Committees
|
| |
Retainer
|
| |||
Marianne Søgaard
|
| | Chairwoman | | | 提名和治理 | | | | $ | 120,667 | | |
Roberto Prego
|
| | Director | | |
提名和治理审计委员会
|
| | | $ | 40,000 | | |
Steven Projan
|
| | Director | | | 审计委员会,薪酬 | | | | $ | 58,542 | | |
Lars Holtug
|
| | Director | | | 审计委员会,薪酬 | | | | $ | 54,875 | | |
Name of Beneficial Owner
|
| |
实益拥有的股份
before The Offering |
| |
实益拥有的股份
after The Offering |
| |
Percent of Shares
Beneficially Owned Assuming Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| |||||||||||||||||||||
|
Number
|
| |
Percent
|
| |
Number
|
| |
Percent
|
| ||||||||||||||||||||
5%或更大股东 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
NIMedical Holding ApS(1)
|
| | | | 4,292,604 | | | | | | 22.36 | | | | | | 4,292,604 | | | | | | 18.97 | | | | | | 18.55 | | |
Mattsson Holding af 2008 ApS(2)
|
| | | | 4,163,832 | | | | | | 21.69 | | | | | | 4,163,832 | | | | | | 18.40 | | | | | | 17.99 | | |
Executive Management
|
| | | | | | | | | | | | | | | | | | | | | | 3.65 | | | | | | 3.57 | | |
Lars Staal Wegner
|
| | | | 182,124 | | | | | | * | | | | | | 182,124 | | | | | | * | | | | | | * | | |
Niels Iverson Møller(1)
|
| | | | 4,292,604 | | | | | | 22.36 | | | | | | 4,292,604 | | | | | | 18.97 | | | | | | 18.55 | | |
Andreas Holm Mattson(2)
|
| | | | 4,163,832 | | | | | | 21.69 | | | | | | 4,163,832 | | | | | | 18.40 | | | | | | 17.99 | | |
Glenn S. Vraniak(3)
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
Birgitte Rønø
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
Erik Deichmann Heegaard
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
Directors | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Roberto Prego
|
| | | | 310,248 | | | | | | 1.62 | | | | | | 310,248 | | | | | | 1.37 | | | | | | 1.34 | | |
Steven Projan
|
| | | | 27,288 | | | | | | * | | | | | | 27,288 | | | | | | * | | | | | | * | | |
Lars Holtug
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
Marianne Søgaard
|
| | | | 41,652 | | | | | | * | | | | | | 41,652 | | | | | | * | | | | | | * | | |
所有现任董事和执行管理层,作为一个小组(10人)
|
| | | | 9,017,748 | | | | | | 46.97 | | | | | | 9,017,748 | | | | | | 39.85 | | | | | | 38.97 | | |
Date
|
| |
Transaction
|
| |
Share Capital
After Transaction |
| |
Price
Per share (DKK) |
| ||||||
August 2008
|
| | Formation (Nominal DKK 1) | | | | | 250,000 | | | | | | 1.00 | | |
March 2014
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 268,148 | | | | | | 120.00 | | |
December 2014
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 316,751 | | | | | | 178.22 | | |
December 2015
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 336,549 | | | | | | 435.76 | | |
March 2016
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 342,880 | | | | | | 432.12 | | |
September 2017
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 358,806 | | | | | | 1,034.75 | | |
March 2019
|
| | 转移储备(名义1丹麦克朗) | | | | | 717,612 | | | | | | 1.00 | | |
July 2019
|
| |
现金出资和债务转换
(Nominal DKK 1) |
| | | | 836,994 | | | |
914.71(avg)
|
| |||
December 2019
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 843,564 | | | | | | 1,037.50 | | |
September 2020
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 884,974 | | | | | | 1,002.90 | | |
October 2020
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 899,926 | | | | | | 1,008.45 | | |
January 2021
|
| | Share split 2-for-1 (Nominal DKK 1) | | | | | 899,926 | | | | | | – | | |
January 2021
|
| |
1送17(名义1丹麦克朗)红股发行
|
| | | | 16,198,668 | | | | | | – | | |
February 2021
|
| | 现金贡献(名义上为1丹麦克朗) | | | | | 19,198,668 | | | | | | 61.84 | | |
June 2021
|
| | | | | | | | | | | | | | | |
Grant Date
|
| |
Vesting Period
|
| |
Expiration Date
|
| |
Exercise Price
|
| |
Number of Warrants
|
| |||
December 19, 2016
|
| |
Fully Vested
|
| |
December 31, 2036
|
| | | | DKK1.0 | | | |
758,448
|
|
December 10, 2017
|
| |
Fully Vested
|
| |
December 31, 2036
|
| | | | DKK1.0 | | | |
632,700
|
|
December 19, 2017
|
| |
Fully Vested
|
| |
December 31, 2036
|
| | | | DKK1.0 | | | |
141,804
|
|
December 17, 2020
|
| |
Upon Exit/1/36 per month
|
| |
December 31, 2036
|
| | | | DKK1.0 | | | |
757,620
|
|
June 17, 2021
未经锻炼即失效或作废 |
| |
1/36 per month
|
| |
December 31, 2031
|
| | | | DKK1.0 | | | |
62,147
(79,112)
2,273,607
|
|
存取款人员
股票或美国存托股份持有人必须支付: |
| |
For:
|
|
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs) | | |
美国存托凭证的发行,包括因股份、权利或其他财产的分配而产生的发行
为取款目的取消美国存托凭证,包括存款协议终止的情况
|
|
$.05 (or less) per ADS | | | 对美国存托股份持有者的任何现金分配 | |
如果分发给您的证券是股票,并且这些股票是为发行美国存托凭证而存放的,则应支付的费用相当于该费用 | | | 由托管人分配给美国存托股份持有人的分配给已存放证券(包括权利)持有人的证券的分配 | |
每个日历年每个美国存托股份$0.05(或更少) | | | 托管服务 | |
注册费或转让费 | | | 当您存入或提取股票时,我们股票登记簿上的股票以托管人或其代理人的名义进行转让和登记 | |
托管人的费用 | | |
电报和传真传输(如果存款协议中明确规定)
将外币兑换成美元
|
|
托管人或托管人必须为任何美国存托凭证或股票支付的税款和其他政府费用,如股票转让税、印花税或预扣税 | | | As necessary | |
托管人或其代理人为已交存证券支付的任何费用 | | | As necessary | |
Underwriter
|
| |
Number of
ADSs |
| |||
Oppenheimer & Co. Inc.
|
| | | | 2,400,000 | | |
Ladenburg Thalmann & Co. Inc.
|
| | | | 600,000 | | |
Lake Street Capital Markets,LLC
|
| | | | 428,571 | | |
Total
|
| | | | 3,428,571 | | |
| | |
Per ADS
|
| |
Total
Without Exercise of Over-Allotment Option |
| |
Total With
Full Exercise of Over-Allotment Option |
| |||||||||
Public offering price
|
| | | $ | 7.00 | | | | | $ | 23,999,997 | | | | | $ | 27,599,992 | | |
承保折扣和佣金
|
| | | $ | 0.42 | | | | | $ | 1,440,000 | | | | | $ | 1,656,000 | | |
未扣除费用的收益给我们
|
| | | $ | 6.58 | | | | | $ | 22,559,997 | | | | | $ | 25,943,992 | | |
Expenses
|
| |
Amount
|
| |||
SEC registration fee
|
| | | $ | 2,559 | | |
FINRA filing fee
|
| | | | 15,500 | | |
印刷费和雕刻费
|
| | | | 190,000 | | |
Legal fees and expenses
|
| | | | 550,000 | | |
会计费和费用
|
| | | | 300,000 | | |
杂项费用
|
| | | | 10,000 | | |
Total
|
| | | $ | 1,068,059 | | |
| | |
Page
|
| |||
经审计的财务报表: | | | | | | | |
独立注册会计师事务所报告
|
| | | | F-2 | | |
Financial Statements:
|
| | | | | | |
截至2018年、2019年和2020年12月31日止年度的全面亏损表
|
| | | | F-3 | | |
截至2019年和2020年12月31日的财务状况表
|
| | | | F-4 | | |
截至2018年、2019年和2020年12月31日止年度的权益变动表
|
| | | | F-5 | | |
截至2018年、2019年和2020年12月31日止年度的现金流量表
|
| | | | F-6 | | |
财务报表附注
|
| | | | F-7 | | |
|
三个年度未经审计的简明合并中期综合损失表
and Six Months Ended June 30, 2021 and 2020 |
| | | | F-38 | | |
|
截至2021年6月30日和2020年12月31日的未经审计简明合并中期财务报表
|
| | | | F-39 | | |
|
第三和第六年度未经审计的简明合并中期权益变动表
Months Ended June 30, 2021 and 2020 |
| | | | F-40 | | |
|
截至2021年6月30日和2020年6月30日的六个月未经审计的简明合并中期现金流表
|
| | | | F-41 | | |
|
未经审计的简明合并中期财务报表附注
|
| | | | F-42 | | |
| | | | | |
Years Ended December 31,
|
| |||||||||||||||
| | |
Note
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
| | |
(单位为千美元,每股除外)
|
| ||||||||||||||||||
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | |
研发
|
| |
6,7
|
| | | $ | 10,902 | | | | | $ | 8,216 | | | | | $ | 3,729 | | |
一般和行政
|
| |
6,7
|
| | | | 5,666 | | | | | | 2,647 | | | | | | 1,898 | | |
总运营费用
|
| | | | | | | 16,568 | | | | | | 10,863 | | | | | | 5,627 | | |
Operating loss
|
| | | | | | | (16,568) | | | | | | (10,863) | | | | | | (5,627) | | |
Finance income
|
| |
9
|
| | | | 216 | | | | | | 65 | | | | | | 76 | | |
Finance expenses
|
| |
9
|
| | | | (223) | | | | | | (1,222) | | | | | | (719) | | |
Net loss before tax
|
| | | | | | | (16,575) | | | | | | (12,020) | | | | | | (6,270) | | |
Income tax benefit
|
| |
10
|
| | | | 1,557 | | | | | | 825 | | | | | | 735 | | |
Net loss for the year
|
| | | | | | $ | (15,018) | | | | | $ | (11,195) | | | | | $ | (5,535) | | |
Evaxion Biotech A/S股东应占净亏损
|
| | | | | | $ | (15,018) | | | | | $ | (11,195) | | | | | $ | (5,535) | | |
可重新分类为利润或
的其他全面收入
后续期间亏损(税后净额): |
| | | | | | | | | | | | | | | | | | | | | |
对外业务翻译汇兑差异
|
| | | | | | | (18) | | | | | | − | | | | | | − | | |
不重新归类为利润的其他全面收入
或后续期间亏损(税后净额): |
| | | | | | | | | | | | | | | | | | | | | |
货币折算成提示货币的汇兑差额
|
| | | | | | | 413 | | | | | | 2 | | | | | | (15) | | |
本年度其他综合亏损,税后净额
|
| | | | | | $ | 395 | | | | | $ | 2 | | | | | $ | (15) | | |
全面亏损
|
| | | | | | $ | (14,623) | | | | | $ | (11,193) | | | | | $ | (5,550) | | |
Evaxion股东应占全面亏损总额
Biotech A/S |
| | | | | | $ | (14,623) | | | | | $ | (11,193) | | | | | $ | (5,550) | | |
Loss per share – basic and diluted
|
| |
11
|
| | | $ | (0.97) | | | | | $ | (0.81) | | | | | $ | (0.43) | | |
| | | | | |
December 31,
|
| |||||||||
| | |
Note
|
| |
2020
|
| |
2019
|
| ||||||
| | | | | |
(USD in thousands)
|
| |||||||||
ASSETS | | | | | | | | | | | | | | | | |
Non-current assets | | | | | | | | | | | | | | | | |
Intangible assets
|
| |
12
|
| | | $ | 100 | | | | | $ | − | | |
Deferred tax assets
|
| |
10
|
| | | | 262 | | | | | | − | | |
财产和设备,净额
|
| |
13
|
| | | | 221 | | | | | | 101 | | |
政府拨款应收账款
|
| | | | | | | 194 | | | | | | − | | |
Leasehold deposits
|
| |
17
|
| | | | 238 | | | | | | 25 | | |
非流动资产合计
|
| | | | | | | 1,015 | | | | | | 126 | | |
Current assets | | | | | | | | | | | | | | | | |
预付款和其他应收款
|
| |
14
|
| | | | 1,971 | | | | | | 575 | | |
延期发售成本
|
| |
1
|
| | | | 1,729 | | | | | | − | | |
Tax receivables
|
| | | | | | | 1,416 | | | | | | 824 | | |
现金和现金等价物
|
| |
16
|
| | | | 5,834 | | | | | | 9,559 | | |
Total current assets
|
| | | | | | | 10,950 | | | | | | 10,958 | | |
TOTAL ASSETS
|
| | | | | | $ | 11,965 | | | | | $ | 11,084 | | |
权益和负债 | | | | | | | | | | | | | | | | |
Share capital
|
| |
18
|
| | | $ | 2,648 | | | | | $ | 2,481 | | |
Other reserves
|
| |
18
|
| | | | 31,669 | | | | | | 22,693 | | |
Accumulated deficit
|
| |
18
|
| | | | (27,279) | | | | | | (15,812) | | |
Total equity
|
| | | | | | | 7,038 | | | | | | 9,362 | | |
流动负债 | | | | | | | | | | | | | | | | |
Lease liabilities
|
| |
17
|
| | | | 20 | | | | | | 36 | | |
Trade payables
|
| | | | | | | 2,646 | | | | | | 646 | | |
Other payables
|
| |
15
|
| | | | 2,261 | | | | | | 1,040 | | |
流动负债总额
|
| | | | | | | 4,927 | | | | | | 1,722 | | |
Total liabilities
|
| | | | | | | 4,927 | | | | | | 1,722 | | |
权益和负债合计
|
| | | | | | $ | 11,965 | | | | | $ | 11,084 | | |
| | | | | | | | | | | |
Other reserves
|
| | | | | | | | | | | | | |||||||||
| | |
Note
|
| |
Share capital
|
| |
Share
premium |
| |
Foreign
currency translation reserve |
| |
Accumulated
deficit |
| |
Total equity
|
| |||||||||||||||
| | | | | |
(USD in thousands)
|
| |||||||||||||||||||||||||||
Equity at January 1, 2018
|
| | | | | | $ | 117 | | | | | $ | 6,102 | | | | | $ | (156) | | | | | | (3,513) | | | | | $ | 2,550 | | |
Bonus share issuance
|
| |
23
|
| | | | 1,996 | | | | | | (1,996) | | | | | | − | | | | | | − | | | | | | − | | |
Equity at January 1, 2018
|
| | | | | | $ | 2,113 | | | | | $ | 4,106 | | | | | $ | (156) | | | | | $ | (3,513) | | | | | $ | 2,550 | | |
Net loss for the year
|
| | | | | | | − | | | | | | − | | | | | | − | | | | | | (5,535) | | | | | | (5,535) | | |
其他综合收益
|
| | | | | | | − | | | | | | − | | | | | | (15) | | | | | | − | | | | | | (15) | | |
基于股份的薪酬
|
| |
9
|
| | | | − | | | | | | − | | | | | | − | | | | | | 2,069 | | | | | | 2,069 | | |
Equity at December 31, 2018
|
| | | | | | $ | 2,113 | | | | | $ | 4,106 | | | | | $ | (171) | | | | | $ | (6,979) | | | | | $ | (931) | | |
Net loss for the year
|
| | | | | | | − | | | | | | − | | | | | | − | | | | | | (11,195) | | | | | | (11,195) | | |
其他综合收益
|
| | | | | | | − | | | | | | − | | | | | | 2 | | | | | | − | | | | | | 2 | | |
基于股份的薪酬
|
| |
8
|
| | | | − | | | | | | − | | | | | | − | | | | | | 2,362 | | | | | | 2,362 | | |
发行股票换取现金
|
| |
18
|
| | | | 181 | | | | | | 9,261 | | | | | | − | | | | | | − | | | | | | 9,442 | | |
Transaction costs
|
| |
18
|
| | | | − | | | | | | (13) | | | | | | − | | | | | | − | | | | | | (13) | | |
可转换债务工具结算
|
| |
20
|
| | | | 187 | | | | | | 9,508 | | | | | | − | | | | | | − | | | | | | 9,695 | | |
Equity at December 31, 2019
|
| | | | | | $ | 2,481 | | | | | $ | 22,862 | | | | | $ | (169) | | | | | $ | (15,812) | | | | | $ | 9,362 | | |
Net loss for the year
|
| | | | | | | − | | | | | | − | | | | | | − | | | | | | (15,018) | | | | | | (15,018) | | |
其他综合收益
|
| | | | | | | − | | | | | | − | | | | | | 395 | | | | | | − | | | | | | 395 | | |
基于股份的薪酬
|
| |
8
|
| | | | − | | | | | | − | | | | | | − | | | | | | 3,551 | | | | | | 3,551 | | |
发行股票换取现金
|
| |
18
|
| | | | 167 | | | | | | 8,853 | | | | | | − | | | | | | − | | | | | | 9,020 | | |
Transaction costs
|
| |
18
|
| | | | − | | | | | | (272) | | | | | | − | | | | | | − | | | | | | (272) | | |
Equity at December 31, 2020
|
| | | | | | $ | 2,648 | | | | | $ | 31,443 | | | | | $ | 226 | | | | | $ | (27,279) | | | | | $ | 7,038 | | |
| | |
Note
|
| |
Years Ended December 31,
|
| |||||||||||||||
| | |
2020
|
| |
2019
|
| |
2018
|
| ||||||||||||
| | | | | |
(USD in thousands)
|
| |||||||||||||||
经营活动: | | | | | | | | | | | | | | | | | | | | | | |
Net loss for the year
|
| | | | | | $ | (15,018) | | | | | $ | (11,195) | | | | | $ | (5,535) | | |
非现金项目调整
|
| |
16
|
| | | | 1,583 | | | | | | 2,945 | | | | | | 2,123 | | |
Interest received
|
| | | | | | | − | | | | | | 9 | | | | | | 2 | | |
Interest paid
|
| | | | | | | (30) | | | | | | (39) | | | | | | (15) | | |
Income taxes received
|
| | | | | | | 812 | | | | | | 688 | | | | | | 453 | | |
工作变更前的经营活动现金流
capital |
| | | | | | | (12,653) | | | | | | (7,592) | | | | | | (2,972) | | |
营运资金变动产生的现金流: | | | | | | | | | | | | | | | | | | | | | | |
净营运资金变动
|
| |
16
|
| | | | 215 | | | | | | 573 | | | | | | 981 | | |
经营活动中使用的净现金
|
| | | | | | | (12,438) | | | | | | (7,019) | | | | | | (1,991) | | |
投资活动: | | | | | | | | | | | | | | | | | | | | | | |
无形资产投资
|
| |
12
|
| | | | (35) | | | | | | − | | | | | | − | | |
购置房产、厂房和设备
|
| |
13
|
| | | | (149) | | | | | | (61) | | | | | | (7) | | |
支付非流动金融资产 - 租赁权
deposits |
| | | | | | | (209) | | | | | | (7) | | | | | | 13 | | |
投资活动净额(现金使用)/提供
|
| | | | | | | (393) | | | | | | (68) | | | | | | 6 | | |
融资活动: | | | | | | | | | | | | | | | | | | | | | | |
股票发行收益
|
| |
18
|
| | | | 9,020 | | | | | | 9,442 | | | | | | 1,092 | | |
与发行股票相关的交易成本
|
| | | | | | | (128) | | | | | | (13) | | | | | | − | | |
发行可转换债务工具所得收益
|
| |
16
|
| | | | − | | | | | | 152 | | | | | | 7,998 | | |
Leasing installments
|
| |
16,17
|
| | | | (74) | | | | | | (73) | | | | | | (63) | | |
融资活动提供的现金净额
|
| | | | | | | 8,818 | | | | | | 9,508 | | | | | | 9,027 | | |
现金和现金等价物净额(减少)/增加
|
| | | | | | | (4,013) | | | | | | 2,421 | | | | | | 7,042 | | |
1月1日的现金和现金等价物
|
| |
16
|
| | | | 9,559 | | | | | | 7,433 | | | | | | 468 | | |
现金和现金等价物的汇率调整
|
| | | | | | | 288 | | | | | | (295) | | | | | | (77) | | |
12月31日的现金和现金等价物
|
| |
16
|
| | | $ | 5,834 | | | | | $ | 9,559 | | | | | $ | 7,433 | | |
补充披露现金流量信息 | | | | | | | | | | | | | | | | | | | | | | |
非现金投融资活动 | | | | | | | | | | | | | | | | | | | | | | |
其他应付款中包含的资本化无形资产
|
| |
12
|
| | | | 60 | | | | | | − | | | | | | − | | |
Assets
|
| |
Useful life
|
|
Properties | | | 资产的租赁期限和使用寿命较短 | |
Other equipment | | | 3 – 6 years | |
| | |
December 31, 2020
|
| |||||||||||||||||||||||||||||||||
|
(USD in thousands)
|
| |||||||||||||||||||||||||||||||||||
|
Carrying
amount |
| |
Contractual
cash flows |
| |
|
| |
1 – 5 years
|
| |
>5 years
|
| |
Total
|
| ||||||||||||||||||||
Lease liabilities
|
| | | $ | 20 | | | | | $ | 20 | | | | | $ | 20 | | | | | $ | – | | | | | $ | – | | | | | $ | 20 | | |
Trade payables
|
| | | | 2,646 | | | | | | 2,646 | | | | | | 2,646 | | | | | | – | | | | | | – | | | | | | 2,646 | | |
Other payables
|
| | | | 180 | | | | | | 180 | | | | | | 180 | | | | | | – | | | | | | – | | | | | | 180 | | |
Total
|
| | | $ | 2,846 | | | | | $ | 2,846 | | | | | $ | 2,846 | | | | | $ | – | | | | | $ | – | | | | | $ | 2,846 | | |
| | |
December 31, 2019
|
| |||||||||||||||||||||||||||||||||
|
(USD in thousands)
|
| |||||||||||||||||||||||||||||||||||
|
Carrying
amount |
| |
Contractual
cash flows |
| |
|
| |
1 – 5 years
|
| |
>5 years
|
| |
Total
|
| ||||||||||||||||||||
Lease liabilities
|
| | | $ | 36 | | | | | $ | 55 | | | | | $ | 55 | | | | | $ | – | | | | | $ | – | | | | | $ | 55 | | |
Trade payables
|
| | | | 646 | | | | | | 646 | | | | | | 646 | | | | | | – | | | | | | – | | | | | | 646 | | |
Other payables
|
| | | | 177 | | | | | | 177 | | | | | | 177 | | | | | | – | | | | | | – | | | | | | 177 | | |
Total
|
| | | $ | 859 | | | | | $ | 878 | | | | | $ | 878 | | | | | $ | – | | | | | $ | – | | | | | $ | 878 | | |
| | |
Years Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
员工工资和福利支出,不包括基于股份的薪酬
|
| | | $ | (3,337) | | | | | $ | (2,586) | | | | | $ | (1,756) | | |
基于股份的薪酬费用
|
| | | | (1,496) | | | | | | (1,021) | | | | | | (896) | | |
Depreciation
|
| | | | (92) | | | | | | (65) | | | | | | (59) | | |
External expenses
|
| | | | (5,977) | | | | | | (4,544) | | | | | | (1,018) | | |
研发费用总额
|
| | | $ | (10,902) | | | | | $ | (8,216) | | | | | $ | (3,729) | | |
| | |
Years Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
员工工资和福利支出,不包括基于股份的薪酬
|
| | | $ | (1,098) | | | | | $ | (517) | | | | | $ | (190) | | |
基于股份的薪酬费用
|
| | | | (1,912) | | | | | | (1,341) | | | | | | (1,173) | | |
专业人员和其他费用
|
| | | | (2,644) | | | | | | (773) | | | | | | (520) | | |
Depreciation
|
| | | | (12) | | | | | | (16) | | | | | | (15) | | |
一般和行政费用合计
|
| | | $ | (5,666) | | | | | $ | (2,647) | | | | | $ | (1,898) | | |
| | |
Years Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
全职员工平均人数
|
| | | | 33 | | | | | | 25 | | | | | | 18 | | |
期末员工人数: | | | | | | | | | | | | | | | | | | | |
丹麦和美国
|
| | | | 35 | | | | | | 31 | | | | | | 20 | | |
期末员工总数
|
| | | | 35 | | | | | | 31 | | | | | | 20 | | |
| | |
Years Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
Wages and salaries
|
| | | $ | 4,016 | | | | | $ | 2,819 | | | | | $ | 1,733 | | |
基于股份的薪酬费用
|
| | | | 3,408 | | | | | | 2,362 | | | | | | 2,069 | | |
已定义的缴费计划
|
| | | | 206 | | | | | | 96 | | | | | | 70 | | |
其他社会保障费用
|
| | | | 17 | | | | | | 12 | | | | | | 10 | | |
Other staff expenses
|
| | | | 196 | | | | | | 176 | | | | | | 133 | | |
Total
|
| | | $ | 7,843 | | | | | $ | 5,465 | | | | | $ | 4,015 | | |
| | |
Years Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
员工总成本分类为: | | | | | | | | | | | | | | | | | | | |
研发费用
|
| | | $ | 4,833 | | | | | $ | 3,607 | | | | | $ | 2,652 | | |
一般和行政费用
|
| | | | 3,010 | | | | | | 1,858 | | | | | | 1,363 | | |
Total
|
| | | $ | 7,843 | | | | | $ | 5,465 | | | | | $ | 4,015 | | |
| | |
Years Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
非管理层员工福利支出分类为: | | | | | | | | | | | | | | | | | | | |
研发费用
|
| | | $ | 4,009 | | | | | $ | 2,590 | | | | | $ | 1,686 | | |
一般和行政费用
|
| | | | 611 | | | | | | 668 | | | | | | 26 | | |
Total
|
| | | $ | 4,620 | | | | | $ | 3,258 | | | | | $ | 1,712 | | |
| | |
Year Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
高管薪酬: | | | | | | | | | | | | | | | | | | | |
Wages and salaries
|
| | | $ | 1,298 | | | | | $ | 900 | | | | | $ | 621 | | |
基于股份的薪酬费用
|
| | | | 1,566 | | | | | | 956 | | | | | | 1,157 | | |
Total
|
| | | | 2,864 | | | | | | 1,856 | | | | | | 1,778 | | |
董事会薪酬:
|
| | | | | | | | | | | | | | | | | | |
基于股份的薪酬费用
|
| | | | 359 | | | | | | 351 | | | | | | 525 | | |
Total
|
| | | | 359 | | | | | | 351 | | | | | | 525 | | |
董事会和执行管理层的薪酬分类为:
|
| | | | | | | | | | | | | | | | | | |
研发费用
|
| | | | 824 | | | | | | 1,017 | | | | | | 965 | | |
一般和行政费用
|
| | | | 2,399 | | | | | | 1,190 | | | | | | 1,338 | | |
Total
|
| | | $ | 3,223 | | | | | $ | 2,207 | | | | | $ | 2,303 | | |
| | |
Number of
warrants |
| |
Weighted
Average Exercise Price/Share (DKK) |
| |
Weighted
Average Remaining Contractual Life (years) |
| ||||||
Warrants granted as at January 1, 2018*
|
| | | | 1,481,796 | | | |
DKK 1
|
| | | | 19 | | |
Warrants granted**
|
| | | | 192,528 | | | |
1
|
| | | | 18 | | |
Warrants granted as at December 31, 2018
|
| | | | 1,674,324 | | | |
1
|
| | | | 18 | | |
Warrants granted**
|
| | | | 257,832 | | | |
1
|
| | | | 17 | | |
Warrants granted as at December 31, 2019
|
| | | | 1,932,156 | | | |
1
|
| | | | 17 | | |
Warrants granted
|
| | | | 363,168 | | | |
1
|
| | | | 11 | | |
Warrants forfeited
|
| | | | (45,216) | | | |
1
|
| | | | 16 | | |
Warrants cancelled
|
| | | | (22,032) | | | |
1
|
| | | | 16 | | |
Warrants granted as at December 31, 2020
|
| | | | 2,228,076 | | | |
DKK 1
|
| | | | 15 | | |
于2019年12月31日可行使的认股权证
|
| | | | – | | | |
–
|
| | | | – | | |
于2020年12月31日可行使的认股权证
|
| | | | – | | | |
–
|
| | | | – | | |
| | |
Years Ended
December 31, |
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
研发费用
|
| | | $ | 1,496 | | | | | $ | 1,021 | | | | | $ | 896 | | |
一般和行政费用
|
| | | | 1,912 | | | | | | 1,341 | | | | | | 1,173 | | |
Total
|
| | | $ | 3,408 | | | | | $ | 2,362 | | | | | $ | 2,069 | | |
Outstanding program
|
| |
Per warrant
grant date fair value (DKK) |
| |
Number of
warrants outstanding |
| |
Average
exercise price per warrant (DKK) |
| |
Remaining
term to maturity (years) |
| ||||||||||||
Grant (December 2016)
|
| | | | 20.91 | | | | | | 712,332 | | | | | | 1 | | | | | | 16 | | |
Grant (April 2017)
|
| | | | 24.05 | | | | | | 13,896 | | | | | | 1 | | | | | | 16 | | |
Grant (September 2017)
|
| | | | 28.71 | | | | | | 617,184 | | | | | | 1 | | | | | | 16 | | |
Grant (December 2017)
|
| | | | 28.71 | | | | | | 127,044 | | | | | | 1 | | | | | | 16 | | |
Grant (during 2018)
|
| | | | 37.05 | | | | | | 181,836 | | | | | | 1 | | | | | | 16 | | |
Grant (February 2019)
|
| | | | 42.57 | | | | | | 7,956 | | | | | | 1 | | | | | | 16 | | |
Grant (September 2019)
|
| | | | 56.35 | | | | | | 54,000 | | | | | | 1 | | | | | | 16 | | |
Grant (October 2019)
|
| | | | 56.97 | | | | | | 150,660 | | | | | | 1 | | | | | | 16 | | |
Grant (December 2020)
|
| | | | 56.75 | | | | | | 363,168 | | | | | | 1 | | | | | | 11 | | |
Granted at December 31, 2020
|
| | | | | | | | | | 2,228,076 | | | | | | 1 | | | | | | 15 | | |
可于2020年12月31日起执行的认股权证
|
| | | | | | | | | | – | | | | | | | | | | | | | | |
Outstanding program
|
| |
Per warrant
grant date fair value (DKK) |
| |
Number of
warrants outstanding |
| |
Average
exercise price per warrant (DKK) |
| |
Remaining
term to maturity (years) |
| ||||||||||||
Grant (December 2016)
|
| | | | 20.91 | | | | | | 712,332 | | | | | | 1 | | | | | | 17 | | |
Grant (April 2017)
|
| | | | 24.05 | | | | | | 13,896 | | | | | | 1 | | | | | | 17 | | |
Grant (September 2017)
|
| | | | 28.71 | | | | | | 617,184 | | | | | | 1 | | | | | | 17 | | |
Grant (December 2017)
|
| | | | 28.71 | | | | | | 138,384 | | | | | | 1 | | | | | | 17 | | |
Grant (during 2018)(1)**
|
| | | | 37.05 | | | | | | 192,528 | | | | | | 1 | | | | | | 17 | | |
Grant (January 2019)(1)**
|
| | | | 37.05 | | | | | | 45,216 | | | | | | 1 | | | | | | 17 | | |
Grant (February 2019)**
|
| | | | 42.57 | | | | | | 7,956 | | | | | | 1 | | | | | | 17 | | |
Grant (September 2019)**
|
| | | | 56.35 | | | | | | 54,000 | | | | | | 1 | | | | | | 17 | | |
Grant (October 2019)**
|
| | | | 56.97 | | | | | | 150,660 | | | | | | 1 | | | | | | 17 | | |
Granted at December 31, 2019
|
| | | | | | | | | | 1,932,156 | | | | | | 1 | | | | | | 17 | | |
可于2019年12月31日起行使的认股权证
|
| | | | | | | | | | – | | | | | | | | | | | | | | |
Outstanding program
|
| |
Per
warrant grant date fair value (DKK) |
| |
Average
Number of warrants outstanding |
| |
Remaining
exercise price per warrant (DKK) |
| |
term to
maturity (years) |
| ||||||||||||
Grant (December 2016)
|
| | | | 20.91 | | | | | | 712,332 | | | | | | 1 | | | | | | 18 | | |
Grant (April 2017)
|
| | | | 24.05 | | | | | | 13,896 | | | | | | 1 | | | | | | 18 | | |
Grant (September 2017)
|
| | | | 28.71 | | | | | | 617,184 | | | | | | 1 | | | | | | 18 | | |
Grant (December 2017)
|
| | | | 28.71 | | | | | | 138,384 | | | | | | 1 | | | | | | 18 | | |
Grant (during 2018)**
|
| | | | 37.05 | | | | | | 192,528 | | | | | | 1 | | | | | | 18 | | |
Granted at December 31, 2018
|
| | | | | | | | | | 1,674,324 | | | | | | 1 | | | | | | 18 | | |
可于2018年12月31日执行的认股权证
|
| | | | | | | | | | – | | | | | | | | | | | | | | |
Number of
warrants held |
| |
January 1,
2018 |
| |
Granted
|
| |
December 31,
2018 |
| |
Granted
|
| |
December 31,
2019 |
| |
Warrants held
when becoming or leaving as a member of management |
| |
Granted
|
| |
Forfeited
|
| |
December 31,
2020 |
| |||||||||||||||||||||||||||
Thomas William Wylonis(1)
|
| | | | 293,364 | | | | | | 49,248 | | | | | | 342,612 | | | | | | – | | | | | | 342,612 | | | | | | (369,252) | | | | | | 26,640 | | | | | | – | | | | | | – | | |
Steven Projan
|
| | | | – | | | | | | 23,436 | | | | | | 23,436 | | | | | | – | | | | | | 23,436 | | | | | | – | | | | | | 18,612 | | | | | | – | | | | | | 42,048 | | |
Roberto Prego
|
| | | | 7,416 | | | | | | 12,384 | | | | | | 19,800 | | | | | | – | | | | | | 19,800 | | | | | | – | | | | | | 14,364 | | | | | | – | | | | | | 34,164 | | |
Joann Suzich
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | 10,260 | | | | | | – | | | | | | 10,260 | | |
Marianne Søgaard(2)
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | 65,952 | | | | | | 28,368 | | | | | | – | | | | | | 94,320 | | |
Helen Boudreau(3)
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | 5,436 | | | | | | – | | | | | | 5,436 | | |
Kim Bjørnstrup (former)(4)
|
| | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | – | | | | | | (5,868) | | | | | | 5,868 | | | | | | – | | | | | | – | | |
董事会总数
|
| | | | 300,780 | | | | | | 85,068 | | | | | | 385,848 | | | | | | – | | | | | | 385,848 | | | | | | (309,168) | | | | | | 109,548 | | | | | | – | | | | | | 186,228 | | |
Lars Aage Staal Wegner
|
| | | | 840,528 | | | | | | 3,888 | | | | | | 844,416 | | | | | | – | | | | | | 844,416 | | | | | | – | | | | | | 7,668 | | | | | | – | | | | | | 852,084 | | |
Thomas Bogenrieder
(former)(5) |
| | | | 4,356 | | | | | | – | | | | | | 4,356 | | | | | | 45,216 | | | | | | 49,572 | | | | | | (4,356) | | | | | | – | | | | | | (45,216) | | | | | | – | | |
Glenn S. Vraniak(6)
|
| | | | – | | | | | | – | | | | | | – | | | | | | 150,660 | | | | | | 150,660 | | | | | | – | | | | | | – | | | | | | – | | | | | | 150,660 | | |
高管管理合计
|
| | | | 844,884 | | | | | | 3,888 | | | | | | 848,772 | | | | | | 195,876 | | | | | | 1,044,648 | | | | | | (4,356) | | | | | | 7,668 | | | | | | (45,216) | | | | | | 1,002,744 | | |
| | |
Year Ended
December 31, |
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
Financial income: | | | | | | | | | | | | | | | | | | | |
Interest income, bank
|
| | | $ | – | | | | | $ | 8 | | | | | $ | 2 | | |
Interest income, other
|
| | | | – | | | | | | 1 | | | | | | – | | |
Foreign exchange gains
|
| | | | 216 | | | | | | 56 | | | | | | 74 | | |
Total financial income
|
| | | | 216 | | | | | | 65 | | | | | | 76 | | |
Financial expenses: | | | | | | | | | | | | | | | | | | | |
Interest expenses
|
| | | | (29) | | | | | | (36)(10) | | | | | | | | |
可转换债务工具公允价值变动
|
| | | | – | | | | | | (1,183) | | | | | | (684) | | |
利息支出、租赁负债
|
| | | | (3) | | | | | | (4) | | | | | | | | |
汇兑损失
|
| | | | (194) | | | | | | – | | | | | | (21) | | |
财务费用总额
|
| | | | (223) | | | | | | (1,222) | | | | | | (719) | | |
Net financial items
|
| | | $ | (7) | | | | | $ | (1,157) | | | | | $ | (643) | | |
| | |
Year Ended
December 31, |
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
所得税费用/(福利)
|
| | | $ | (1,557) | | | | | $ | (825) | | | | | $ | (735) | | |
本年度所得税总额
|
| | | $ | (1,557) | | | | | $ | (825) | | | | | $ | (735) | | |
| | |
Year Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
丹麦法定企业所得税税率
|
| | | | 22% | | | | | | 22% | | | | | | 22% | | |
不可扣除的收入/(费用)
|
| | | | (1)% | | | | | | (5)% | | | | | | (10)% | | |
免税收入/(费用)
|
| | | | 1% | | | | | | – | | | | | | – | | |
附加减税研发费用
|
| | | | 3% | | | | | | – | | | | | | – | | |
税收抵免研发支出
|
| | | | 9% | | | | | | 7% | | | | | | 12% | | |
未资本化的递延税项资产变动
|
| | | | (25)% | | | | | | (17)% | | | | | | (12)% | | |
Total effective tax rate
|
| | | | 9% | | | | | | 7% | | | | | | 12% | | |
| | |
Year Ended
December 31, |
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||
递延纳税头寸: | | | | | | | | | | | | | | | | | | | |
Warrants
|
| | | $ | 4,289 | | | | | $ | 3,034 | | | | | $ | 1,463 | | |
Loss carry forward
|
| | | | 3,759 | | | | | | 1,270 | | | | | | 136 | | |
研发支出
|
| | | | 262 | | | | | | – | | | | | | – | | |
Other items
|
| | | | (6) | | | | | | (34) | | | | | | 48 | | |
递延税项资产计价准备
|
| | | | (8,042) | | | | | | (4,270) | | | | | | (1,647) | | |
Total capitalized
|
| | | $ | 262 | | | | | $ | – | | | | | $ | – | | |
| | |
Year Ended December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
| | |
(美元以千为单位,不包括股份金额
and per share amounts) |
| |||||||||||||||
稀释前后每股亏损 | | | | | | | | | | | | | | | | | | | |
Evaxion Biotech A/S股东应占净亏损
|
| | | $ | (15,018) | | | | | $ | (11,195) | | | | | $ | (5,535) | | |
加权平均普通股数量
outstanding |
| | | | 15,434,758 | | | | | | 13,892,314 | | | | | | 12,917,016 | | |
稀释前后每股亏损
|
| | | $ | (0.97) | | | | | $ | (0.81) | | | | | $ | (0.43) | | |
| | |
December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
Warrants
|
| | | | 2,228,076 | | | | | | 2,059,128 | | | | | | 1,674,324 | | |
Convertible Debt l
|
| | | | – | | | | | | – | | | | | | 302,976 | | |
Convertible Debt 2
|
| | | | – | | | | | | – | | | | | | 827,856 | | |
| | |
Intangible
Assets |
| |
Total
|
| ||||||
|
(USD in thousands)
|
| |||||||||||
Cost at December 31, 2019
|
| | | $ | – | | | | | $ | – | | |
本年度新增数量
|
| | | | 95 | | | | | | 95 | | |
汇率调整
|
| | | | 5 | | | | | | 5 | | |
Cost at December 31, 2020
|
| | | | 100 | | | | | | 100 | | |
Amortization at December 31, 2019
|
| | | | – | | | | | | – | | |
本年度摊销
|
| | | | – | | | | | | – | | |
汇率调整
|
| | | | – | | | | | | – | | |
Amortization at December 31, 2020
|
| | | | – | | | | | | – | | |
Carrying amount at December 31, 2020
|
| | | $ | 100 | | | | | $ | 100 | | |
| | |
Property
|
| |
Other
Equipment |
| |
Total
|
| |||||||||
|
(USD in thousands)
|
| |||||||||||||||||
Cost at December 31, 2019
|
| | | $ | 179 | | | | | $ | 93 | | | | | $ | 272 | | |
本年度新增数量
|
| | | | 55 | | | | | | 149 | | | | | | 204 | | |
汇率调整
|
| | | | 23 | | | | | | 21 | | | | | | 44 | | |
Cost at December 31, 2020
|
| | | | 257 | | | | | | 263 | | | | | | 520 | | |
Depreciation at December 31, 2019
|
| | | | (144) | | | | | | (27) | | | | | | (171) | | |
本年度折旧
|
| | | | (71) | | | | | | (34) | | | | | | (105) | | |
汇率调整
|
| | | | (22) | | | | | | (1) | | | | | | (23) | | |
Depreciation at December 31, 2020
|
| | | | (237) | | | | | | (64) | | | | | | (299) | | |
Carrying amount at December 31, 2020
|
| | | $ | 20 | | | | | $ | 201 | | | | | $ | 221 | | |
2020年12月31日使用权资产账面金额
|
| | | $ | 20 | | | | | $ | – | | | | | $ | 20 | | |
| | |
Property
|
| |
Other
Equipment |
| |
Total
|
| |||||||||
|
(USD in thousands)
|
| |||||||||||||||||
Cost at January 1, 2019
|
| | | $ | 171 | | | | | $ | 32 | | | | | $ | 203 | | |
本年度新增数量
|
| | | | 12 | | | | | | 61 | | | | | | 73 | | |
汇率调整
|
| | | | (4) | | | | | | – | | | | | | (4) | | |
Cost at December 31, 2019
|
| | | | 179 | | | | | | 93 | | | | | | 272 | | |
Depreciation at January 1, 2019
|
| | | | (79) | | | | | | (13) | | | | | | (92) | | |
本年度折旧
|
| | | | (67) | | | | | | (14) | | | | | | (81) | | |
汇率调整
|
| | | | 2 | | | | | | – | | | | | | 2 | | |
Depreciation at December 31, 2019
|
| | | | (144) | | | | | | (27) | | | | | | (171) | | |
Carrying amount at December 31, 2019
|
| | | $ | 35 | | | | | $ | 66 | | | | | $ | 101 | | |
2019年12月31日使用权资产账面金额
|
| | | $ | 35 | | | | | $ | – | | | | | $ | 35 | | |
| | |
Year Ended
December 31, |
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
|
(USD in thousands)
|
| |||||||||||||||||
研发
|
| | | $ | 90 | | | | | $ | 64 | | | | | $ | 58 | | |
一般和行政
|
| | | | 15 | | | | | | 16 | | | | | | 15 | | |
全面损失表中包含的折旧总额
|
| | | $ | 105 | | | | | $ | 80 | | | | | $ | 73 | | |
12月31日使用权资产累计折旧总额
|
| | | $ | 236 | | | | | $ | 145 | | | | | $ | 79 | | |
| | |
December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
|
(USD in thousands)
|
| |||||||||||
VAT receivables
|
| | | $ | 376 | | | | | $ | 75 | | |
Prepayments
|
| | | | 1,175 | | | | | | 451 | | |
向临床研究机构预付款项
|
| | | | 418 | | | | | | 17 | | |
Other receivables
|
| | | | 2 | | | | | | 32 | | |
预付款和其他应收款合计
|
| | | $ | 1,971 | | | | | $ | 575 | | |
| | |
December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
|
(USD in thousands)
|
| |||||||||||
支付给临床研究机构的款项
|
| | | $ | 1,027 | | | | | $ | 588 | | |
员工成本负债
|
| | | | 1,054 | | | | | | 275 | | |
Other liabilities
|
| | | | 180 | | | | | | 177 | | |
Total other payables
|
| | | $ | 2,261 | | | | | $ | 1,040 | | |
| | |
December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
|
(USD in thousands)
|
| |||||||||||
现金和现金等价物
|
| | | $ | 5,834 | | | | | $ | 9,559 | | |
现金和现金等价物合计
|
| | | $ | 5,834 | | | | | $ | 9,559 | | |
| | |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
|
(USD in thousands)
|
| |||||||||||||||||
应收账款和应收税金的变动
|
| | | $ | (2,501) | | | | | $ | (337) | | | | | $ | 443 | | |
贸易应付款变更
|
| | | | 1,798 | | | | | | 507 | | | | | | 79 | | |
其他应付款的更改
|
| | | | 918 | | | | | | 403 | | | | | | 459 | | |
净营运资金变动
|
| | | $ | 215 | | | | | $ | 573 | | | | | $ | 981 | | |
| | |
Year Ended
December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
|
(USD in thousands)
|
| |||||||||||||||||
Income taxes
|
| | | $ | (1,557) | | | | | $ | (825) | | | | | $ | (735) | | |
税收抵免方案作为赠款入账
|
| | | | (510) | | | | | | – | | | | | | – | | |
折旧及摊销
|
| | | | 105 | | | | | | 81 | | | | | | 74 | | |
Interest income
|
| | | | – | | | | | | (9) | | | | | | (2) | | |
Interest expense
|
| | | | 30 | | | | | | 39 | | | | | | 15 | | |
基于股份的薪酬费用
|
| | | | 3,408 | | | | | | 2,362 | | | | | | 2,069 | | |
可转换债务工具公允价值变动
|
| | | | – | | | | | | 1,183 | | | | | | 684 | | |
其他调整:其他调整,主要是汇率调整
|
| | | | 107 | | | | | | 114 | | | | | | 18 | | |
非现金项目调整合计
|
| | | $ | 1,583 | | | | | $ | 2,945 | | | | | $ | 2,123 | | |
(USD in thousands)
|
| |
December 31,
2019 |
| |
Cash flows
|
| |
Accumulated
interest |
| |
Additions
|
| |
Exchange rate
adjustment |
| |
December 31,
2020 |
| ||||||||||||||||||
Lease liabilities
|
| | | $ | 36 | | | | | $ | (74) | | | | | $ | 1 | | | | | $ | 54 | | | | | $ | 3 | | | | | $ | 20 | | |
融资活动的总负债
|
| | | $ | 36 | | | | | $ | (74) | | | | | $ | 1 | | | | | $ | 54 | | | | | $ | 3 | | | | | $ | 20 | | |
(USD in thousands)
|
| |
December 31,
2018 |
| |
Cash flows
|
| |
Accumulated
interest |
| |
Fair value
adjustment |
| |
Additions
|
| |
Conversion
|
| |
Exchange rate
adjustment |
| |
December 31,
2019 |
| ||||||||||||||||||||||||
Lease liabilities
|
| | | $ | 99 | | | | | $ | (75) | | | | | $ | 2 | | | | | $ | – | | | | | $ | 12 | | | | | $ | – | | | | | $ | (2) | | | | | $ | 36 | | |
可转换债务工具
|
| | | | 8,569 | | | | | | 152 | | | | | | – | | | | | | 1,183 | | | | | | – | | | | | | (9,695) | | | | | | (209) | | | | | | – | | |
融资活动的总负债
|
| | | $ | 8,668 | | | | | $ | 77 | | | | | $ | 2 | | | | | $ | 1,183 | | | | | $ | 12 | | | | | $ | (9,695) | | | | | $ | (211) | | | | | $ | 36 | | |
| | |
Right-of-Use Asset
|
| |
Lease liabilities
|
| ||||||
|
(USD in thousands)
|
| |||||||||||
At December 31, 2019
|
| | | $ | 35 | | | | | $ | 36 | | |
Additions
|
| | | | 54 | | | | | | 54 | | |
Depreciation
|
| | | | (73) | | | | | | – | | |
Interest Expense
|
| | | | – | | | | | | – | | |
Payments
|
| | | | 4 | | | | | | (74) | | |
Translation
|
| | | | – | | | | | | 4 | | |
At December 31, 2020
|
| | | $ | 20 | | | | | $ | 20 | | |
| | |
Right-of-Use Asset
|
| |
Lease liabilities
|
| ||||||
|
(USD in thousands)
|
| |||||||||||
At January 1, 2019
|
| | | $ | 92 | | | | | $ | 99 | | |
Additions
|
| | | | 12 | | | | | | 12 | | |
Depreciation
|
| | | | (67) | | | | | | – | | |
Interest Expense
|
| | | | – | | | | | | 2 | | |
Payments
|
| | | | – | | | | | | (75) | | |
Translation
|
| | | | (2) | | | | | | (2) | | |
At December 31, 2019
|
| | | $ | 35 | | | | | $ | 36 | | |
| | |
Number of
Ordinary Shares |
| |
Share Capital
(DKK in thousands) |
| ||||||
Share capital, January 1, 2018
|
| | | | 12,917,016 | | | | | | 12,917 | | |
Share capital, December 31, 2018
|
| | | | 12,917,016 | | | | | | 12,917 | | |
2019年7月17日增资(发行股票换现金)
|
| | | | 997,668 | | | | | | 998 | | |
2019年7月17日增资(可转债转换1)
|
| | | | 302,976 | | | | | | 303 | | |
2019年7月17日增资(可转债转换2)
|
| | | | 848,232 | | | | | | 848 | | |
2019年12月19日增资(发行股票换现金)
|
| | | | 118,260 | | | | | | 118 | | |
Share capital, December 31, 2019
|
| | | | 15,184,152 | | | | | | 15,184 | | |
2020年9月17日增资(发行股票换现金)
|
| | | | 745,380 | | | | | | 745 | | |
2020年10月15日增资(发行股票换现金)
|
| | | | 269,136 | | | | | | 269 | | |
Share capital, December 31, 2020
|
| | | | 16,198,668 | | | | | | 16,198 | | |
| | |
December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
|
(USD in thousands)
|
| |||||||||||
授权、签发和全额支付
|
| | | | | | | | | | | | |
16,198,668 (2019:15,184,152) ordinary shares of DKK 1 each (2019: ordinary shares
of DKK 1 each) |
| | | $ | 2,648 | | | | | $ | 2,481 | | |
| | | | $ | 2,648 | | | | | $ | 2,481 | | |
拥有的普通股数量
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
Niels Iversen Møller
|
| | | | 4,292,604 | | | | | | 4,292,604 | | | | | | 4,292,352 | | |
Andreas Holm Mattsson
|
| | | | 4,163,832 | | | | | | 4,163,832 | | | | | | 4,163,832 | | |
Lars Aage Staal Wegner
|
| | | | 182,124 | | | | | | 182,124 | | | | | | 181,872 | | |
高管管理合计
|
| | | | 8,638,560 | | | | | | 8,638,560 | | | | | | 8,638,056 | | |
拥有的普通股数量
|
| |
2020
|
| |
2019
|
| |
2018
|
| |||||||||
Roberto Prego
|
| | | | 676,620 | | | | | | 310,248 | | | | | | 307,548 | | |
Thomas William Wylonis
|
| | | | 485,676 | | | | | | 481,860 | | | | | | 471,096 | | |
Marianne Søgaard
|
| | | | 41,652 | | | | | | – | | | | | | – | | |
Steven Projan
|
| | | | 27,288 | | | | | | 11,736 | | | | | | – | | |
董事会总数
|
| | | | 1,231,236 | | | | | | 803,844 | | | | | | 778,644 | | |
| | |
Convertible loans
|
| | |||||
|
(USD in thousands)
|
| | |||||||
Carrying amount at January 1, 2018
|
| | | $ | – | | | | ||
Amount received in 2018
|
| | | | 7,998 | | | | ||
计入财务费用的公允价值调整
|
| | | | 684 | | | | ||
Currency adjustment
|
| | | | (113) | | | | ||
Carrying amount at December 31, 2018
|
| | | | 8,569 | | | | ||
Amount received in 2019
|
| | | | 152 | | | | ||
计入财务费用的公允价值调整
|
| | | | 1,183 | | | | ||
Currency adjustment
|
| | | | (209) | | | | ||
Converted to equity during 2019
|
| | | | (9,695) | | | | ||
Carrying amount at December 31, 2019
|
| | | $ | – | | | | ||
| | | | | | | | | | |
| | |
Assumption
applied |
|
DKK/USD exchange rate
|
| |
0.154
|
|
Discount rate
|
| |
Convertible Debt 1 – 39%
|
|
| | |
Convertible Debt 2 – 25%
|
|
符合条件的融资事件发生的概率
|
| |
95%
|
|
Evaxion share price
|
| |
$207
|
|
| | |
Impact on
Convertible Debt 1 |
| |
Impact on
Convertible Debt 2 |
| ||||||
|
(USD in thousands)
|
| |||||||||||
Exchange rate increased by 5%
|
| | | $ | (48) | | | | | $ | (272) | | |
Exchange rate decreased by 5%
|
| | | $ | 48 | | | | | $ | 272 | | |
Discount rate decreased by 3%
|
| | | $ | (24) | | | | | $ | (85) | | |
融资事件概率降低25%
|
| | | $ | (100) | | | | | $ | (40) | | |
Share price increased by 10%
|
| | | $ | (10) | | | | | $ | (39) | | |
Share price decreased by 10%
|
| | | $ | 10 | | | | | $ | 39 | | |
| | |
December 31,
|
| |||||||||||||||
|
2020
|
| |
2019
|
| |
2018
|
| |||||||||||
|
(USD in thousands)
|
| |||||||||||||||||
公司与其他关联方的交易: | | | | | | | | | | | | | | | | | | | |
关联方交易(费用):
|
| | | | | | | | | | | | | | | | | | |
发行给高管成员的可转换债务工具的应计利息
管理层和董事会 |
| | | $ | – | | | | | $ | (4) | | | | | $ | (4) | | |
年末关联方余额(资产): | | | | | | | | | | | | | | | | | | | |
从关联方处预付租赁物业的租金和押金
|
| | | $ | 7 | | | | | $ | – | | | | | $ | – | | |
年末关联方余额(负债): | | | | | | | | | | | | | | | | | | | |
向执行管理层和董事会成员发行的可转换债务工具(名义价值外加7.5%的应计利息)
|
| | | $ | – | | | | | $ | – | | | | | $ | 117 | | |
| | |
December 31, 2020
|
| |||||||||||||||||||||||||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||||||||||||||||||||
| | |
Contractual
cash flows |
| |
|
| |
1 – 2 years
|
| |
2 – 5 years
|
| |
>5 years
|
| |
Total
|
| ||||||||||||||||||
Purchase obligations
|
| | | $ | 712 | | | | | $ | 712 | | | | | $ | – | | | | | $ | – | | | | | $ | – | | | | | $ | 712 | | |
Total
|
| | | $ | 712 | | | | | $ | 712 | | | | | $ | – | | | | | $ | – | | | | | $ | – | | | | | $ | 712 | | |
| | |
December 31,
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
|
(USD in thousands)
|
| |||||||||||
Audit fees
|
| | | $ | 308 | | | | | $ | 73 | | |
Audit related fees
|
| | | | 119 | | | | | | – | | |
Other fees
|
| | | | 253 | | | | | | – | | |
Total fees
|
| | | $ | 680 | | | | | $ | 73 | | |
| | |
Three Months Ended
June 30, |
| |
Six Months Ended
June 30, |
| ||||||||||||||||||
| | |
2020
|
| |
2021
|
| |
2020
|
| |
2021
|
| ||||||||||||
| | |
(单位为千美元,每股除外)
|
| |||||||||||||||||||||
Operating expenses: | | | | | | ||||||||||||||||||||
研发
|
| | | $ | 2,570 | | | | | $ | 5,111 | | | | | $ | 5,080 | | | | | $ | 9,004 | | |
一般和行政
|
| | | | 1,372 | | | | | | 1,915 | | | | | | 2,153 | | | | | | 3,197 | | |
总运营费用
|
| | | | 3,942 | | | | | | 7,026 | | | | | | 7,233 | | | | | | 12,201 | | |
Operating loss
|
| | | | (3,942) | | | | | | (7,026) | | | | | | (7,233) | | | | | | (12,201) | | |
Finance income
|
| | | | 6 | | | | | | 33 | | | | | | 22 | | | | | | 1,005 | | |
Finance expenses
|
| | | | — | | | | | | (495) | | | | | | (4) | | | | | | (792) | | |
Net loss before tax
|
| | | | (3,936) | | | | | | (7,488) | | | | | | (7,215) | | | | | | (11,988) | | |
Income tax benefit
|
| | | | 296 | | | | | | 669 | | | | | | 476 | | | | | | 1,076 | | |
Net loss for the period
|
| | | $ | (3,640) | | | | | $ | (6,819) | | | | | $ | (6,739) | | | | | $ | (10,912) | | |
Evaxion Biotech A/S股东应占净亏损
|
| | | $ | (3,640) | | | | | $ | (6,819) | | | | | $ | (6,739) | | | | | $ | (10,912) | | |
后续期间可能重新分类为损益的其他全面收益:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
对外业务翻译汇兑差异
|
| | | | (10) | | | | | | (57) | | | | | | (10) | | | | | | (28) | | |
其他综合所得征税
|
| | | | — | | | | | | 6 | | | | | | — | | | | | | — | | |
后续期间不重新计入损益的其他全面收益:
|
| | | | | | | | | | | | | | | | | | | | | | | | |
货币折算成提示货币的汇兑差额
|
| | | | 109 | | | | | | 474 | | | | | | (71) | | | | | | (284) | | |
当期其他综合亏损,税后净额
|
| | | $ | 99 | | | | | $ | 423 | | | | | $ | (81) | | | | | $ | (312) | | |
全面亏损
|
| | | $ | (3,541) | | | | | $ | (6,396) | | | | | $ | (6,820) | | | | | $ | (11,224) | | |
Evaxion股东应占全面亏损总额
Biotech A/S |
| | | $ | (3,541) | | | | | $ | (6,396) | | | | | $ | (6,820) | | | | | $ | (11,224) | | |
Loss per share – basic and diluted
|
| | | $ | (0.24) | | | | | $ | (0.36) | | | | | $ | (0.44) | | | | | $ | (0.59) | | |
| | |
Note
|
| |
December 31,
2020 |
| |
June 30,
2021 |
| |||||||||
| | | | | | | | |
(USD in thousands)
|
| |||||||||
ASSETS | | | | | | | | | | | | | | | | | | | |
Non-current assets | | | | | | | | | | | | | | | | | | | |
Intangible assets
|
| | | | | | | | | $ | 100 | | | | | $ | 97 | | |
Deferred tax assets
|
| | | | | | | | | | 262 | | | | | | 252 | | |
Property and equipment
|
| | |
|
2
|
| | | | | 221 | | | | | | 2,076 | | |
应收政府补助金
|
| | | | | | | | | | 194 | | | | | | 549 | | |
Tax receivables
|
| | | | | | | | | | — | | | | | | 1,058 | | |
Leasehold deposits
|
| | | | | | | | | | 238 | | | | | | 200 | | |
非流动资产合计 | | | | | | | | | | | 1,015 | | | | | | 4,232 | | |
Current assets | | | | | | | | | | | | | | | | | | | |
预付款和其他应收款
|
| | | | | | | | | | 1,553 | | | | | | 2,564 | | |
延期发售成本
|
| | | | | | | | | | 1,729 | | | | | | 265 | | |
应收政府补助金
|
| | | | | | | | | | 418 | | | | | | 421 | | |
Tax receivables
|
| | | | | | | | | | 1,416 | | | | | | 1,376 | | |
现金和现金等价物
|
| | | | | | | | | | 5,834 | | | | | | 18,799 | | |
Total current assets
|
| | | | | | | | | | 10,950 | | | | | | 23,425 | | |
TOTAL ASSETS
|
| | | | | | | | | $ | 11,965 | | | | | $ | 27,657 | | |
权益和负债 | | | | | | | | | | | | | | | | | | | |
Share capital
|
| | |
|
6
|
| | | | $ | 2,648 | | | | | $ | 3,132 | | |
Other reserves
|
| | | | | | | | | | 31,669 | | | | | | 56,168 | | |
Accumulated deficit
|
| | | | | | | | | | (27,279) | | | | | | (37,471) | | |
Total equity
|
| | | | | | | | | | 7,038 | | | | | | 21,829 | | |
非流动负债 | | | | | | | | | | | | | | | | | | | |
Lease liabilities
|
| | | | | | | | | | — | | | | | | 974 | | |
Provisions
|
| | | | | | | | | | — | | | | | | 53 | | |
非流动负债合计
|
| | | | | | | | | | — | | | | | | 1,027 | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
Lease liabilities
|
| | | | | | | | | | 20 | | | | | | 136 | | |
Trade payables
|
| | | | | | | | | | 2,646 | | | | | | 1,552 | | |
Other payables
|
| | | | | | | | | | 2,261 | | | | | | 3,113 | | |
流动负债总额
|
| | | | | | | | | | 4,927 | | | | | | 4,801 | | |
Total liabilities
|
| | | | | | | | | | 4,927 | | | | | | 5,828 | | |
权益和负债合计
|
| | | | | | | | | $ | 11,965 | | | | | $ | 27,657 | | |
| | | | | | | | | | | | | | | | | | | | |
Other reserves
|
| | | |||||||||||||
| | |
Note
|
| |
Share
capital |
| |
Share
premium |
| |
Foreign
currency translation reserve |
| |
Accumulated
Deficit |
| |
Total
equity |
| ||||||||||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||||||||||||||||||||
Equity at December 31, 2019
|
| | | | | | | | | $ | 2,481 | | | | | $ | 22,862 | | | | | $ | (169) | | | | | $ | (15,812) | | | | | $ | 9,362 | | |
Net loss for the period
|
| | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,099) | | | | | | (3,099) | | |
其他综合收益
|
| | | | | | | | | | — | | | | | | — | | | | | | (180) | | | | | | — | | | | | | (180) | | |
基于股份的薪酬
|
| | |
|
5
|
| | | | | — | | | | | | — | | | | | | — | | | | | | 680 | | | | | | 680 | | |
Equity at March 31, 2020
|
| | | | | | | | | $ | 2,481 | | | | | $ | 22,862 | | | | | $ | (349) | | | | | $ | (18,231) | | | | | $ | 6,763 | | |
Net loss for the period
|
| | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | (3,640) | | | | | | (3,640) | | |
其他综合收益
|
| | | | | | | | | | — | | | | | | — | | | | | | 99 | | | | | | — | | | | | | 99 | | |
基于股份的薪酬
|
| | |
|
5
|
| | | | | — | | | | | | — | | | | | | — | | | | | | 495 | | | | | | 495 | | |
Equity at June 30, 2020
|
| | | | | | | | | $ | 2,481 | | | | | $ | 22,862 | | | | | $ | (250) | | | | | $ | (21,376) | | | | | $ | 3,717 | | |
| | | | | | | | | | | | | | | | | | | | |
Other reserves
|
| | | | | | | | | | | | | |||
| | |
Note
|
| |
Share
capital |
| |
Share
premium |
| |
Foreign
currency translation reserve |
| |
Accumulated
Deficit |
| |
Total
equity |
| ||||||||||||||||||
| | |
(USD in thousands)
|
| |||||||||||||||||||||||||||||||||
Equity at December 31, 2020
|
| | | | | | | | | $ | 2,648 | | | | | $ | 31,443 | | | | | $ | 226 | | | | | $ | (27,279) | | | | | $ | 7,038 | | |
Net loss for the period
|
| | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | (4,093) | | | | | | (4,093) | | |
其他综合收益
|
| | | | | | | | | | — | | | | | | — | | | | | | (729) | | | | | | — | | | | | | (729) | | |
税收对其他综合收益的影响
|
| | | | | | | | | | — | | | | | | — | | | | | | (6) | | | | | | — | | | | | | (6) | | |
基于股份的薪酬
|
| | |
|
5
|
| | | | | — | | | | | | — | | | | | | — | | | | | | 294 | | | | | | 294 | | |
发行股票换取现金
|
| | | | | | | | | | 484 | | | | | | 29,516 | | | | | | — | | | | | | — | | | | | | 30,000 | | |
Transaction costs
|
| | | | | | | | | | — | | | | | | (4,705) | | | | | | — | | | | | | — | | | | | | (4,705) | | |
Equity at March 31, 2021
|
| | | | | | | | | $ | 3,132 | | | | | $ | 56,254 | | | | | $ | (509) | | | | | $ | (31,078) | | | | | $ | 27,799 | | |
Net loss for the period
|
| | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | (6,819) | | | | | | (6,819) | | |
其他综合收益
|
| | | | | | | | | | — | | | | | | — | | | | | | 417 | | | | | | — | | | | | | 417 | | |
税收对其他综合收益的影响
|
| | | | | | | | | | — | | | | | | — | | | | | | 6 | | | | | | — | | | | | | 6 | | |
基于股份的薪酬
|
| | |
|
5
|
| | | | | — | | | | | | — | | | | | | — | | | | | | 426 | | | | | | 426 | | |
Equity at June 30, 2021
|
| | | | | | | | | $ | 3,132 | | | | | $ | 56,254 | | | | | $ | (86) | | | | | $ | (37,471) | | | | | $ | 21,829 | | |
| | |
Six Months Ended
June 30, |
| |||||||||
|
2020
|
| |
2021
|
| ||||||||
|
(USD in thousands)
|
| |||||||||||
经营活动: | | | | | | | | | | | | | |
Net loss for the period
|
| | | $ | (6,739) | | | | | $ | (10,912) | | |
非现金项目调整
|
| | | | 735 | | | | | | (908) | | |
Income taxes received
|
| | | | 812 | | | | | | — | | |
Interest paid
|
| | | | — | | | | | | (3) | | |
营运资金变动前的经营活动现金流
|
| | | | (5,192) | | | | | | (11,823) | | |
营运资金变动产生的现金流: | | | | | | | | | | | | | |
净营运资金变动
|
| | | | (61) | | | | | | 300 | | |
经营活动中使用的净现金
|
| | | | (5,253) | | | | | | (11,523) | | |
投资活动: | | | | | | | | | | | | | |
无形资产投资
|
| | | | (35) | | | | | | (60) | | |
购置物业和设备
|
| | | | (74) | | | | | | (792) | | |
非流动金融资产 - 租赁保证金收(付)款
|
| | | | (17) | | | | | | 30 | | |
投资活动中使用的净现金
|
| | | | (126) | | | | | | (822) | | |
融资活动: | | | | | | | | | | | | | |
股票发行收益
|
| | | | — | | | | | | 27,900 | | |
与发行股票相关的交易成本
|
| | | | — | | | | | | (2,605) | | |
Leasing installments
|
| | | | (36) | | | | | | (78) | | |
由融资活动提供/(用于)融资活动的净现金
|
| | | | (36) | | | | | | 25,217 | | |
现金和现金等价物净增加/(减少)
|
| | | | (5,415) | | | | | | 12,872 | | |
1月1日的现金和现金等价物
|
| | | | 9,559 | | | | | | 5,834 | | |
现金和现金等价物的汇率调整
|
| | | | (59) | | | | | | 93 | | |
6月30日的现金和现金等价物
|
| | | $ | 4,085 | | | | | $ | 18,799 | | |
Assets
|
| |
Useful life
|
|
Properties | | | 资产的租赁期限和使用寿命较短 | |
Other equipment | | | 3 – 6 years | |
| | |
Number of
warrants |
| |
Weighted Average
Exercise Price/Share (DKK) |
| ||||||
Warrants granted as at December 31, 2019
|
| | | | 1,932,156 | | | | | | 1 | | |
Warrants granted
|
| | | | – | | | | | | 1 | | |
Warrants forfeited
|
| | | | (45,216) | | | | | | 1 | | |
Warrants cancelled
|
| | | | (22,032) | | | | | | 1 | | |
Warrants granted as at June 30, 2020
|
| | | | 1,864,908 | | | | | | 1 | | |
Warrants exercisable as at June 30, 2020
|
| | | | – | | | | | | − | | |
| | |
Number of
warrants |
| |
Weighted Average
Exercise Price/Share (DKK) |
| ||||||
Warrants granted as at December 31, 2020
|
| | | | 2,228,076 | | | | | | 1 | | |
Warrants granted
|
| | | | 63,809 | | | | | | 1 | | |
Warrants forfeited
|
| | | | (7,566) | | | | | | 1 | | |
Warrants cancelled
|
| | | | (10,404) | | | | | | 1 | | |
Warrants granted as at June 30, 2021
|
| | | | 2,273,915 | | | | | | 1 | | |
Warrants exercisable as at June 30, 2021
|
| | | | – | | | | | | − | | |
| | |
Number of
Ordinary Shares |
| |
Share Capital
(DKK in thousands) |
| ||||||
Share capital, December 31, 2020
|
| | | | 16,198,668 | | | | | | 16,198 | | |
2021年2月9日首次公开发行增资
|
| | | | 3,000,000 | | | | | | 3,000 | | |
Share capital, June 30, 2021
|
| | | | 19,198,668 | | | | | | 19,198 | | |